Turkish Journal of Pharmaceutical Sciences is published six times a year, in February, April, June, August, October, and December. The journal publishes research articles, invited reviews, preliminary results, short communications, technical notes, and letters to the editor in all fields of pharmaceutical sciences.
The publication language of the journal is English.
The Turkish Journal of Pharmaceutical Sciences does not charge any article submission or processing charges.
A manuscript will be considered only with the understanding that it is an original contribution that has not been published elsewhere.
The Journal should be abbreviated as “Turk J Pharm Sci” when referenced.
As of 2022, authors are not required to provide Turkish Abstracts during manuscript submission.
Authors retain the copyright of their manuscripts and are responsible for the scientific and ethical content of their work, as well as for the accuracy of the references. The commercial rights related to the published manuscripts belong to the Turkish Pharmacists’ Association, Academy of Pharmacy, as specified in the Copyright Agreement Form.
All manuscripts submitted for publication must be accompanied by the Copyright Agreement Form signed by all authors. By submitting this form, authors confirm that the manuscript and the data it contains have not been submitted elsewhere or previously published, that all authors have approved the final version of the manuscript, and that all authors have declared their scientific contributions and responsibilities.
Studies requiring ethics committee approval must include the name of the ethics committee, approval date, and approval number in the Materials and Methods section. For studies involving human participants, authors must state that the study was conducted in accordance with the Declaration of Helsinki and that informed consent was obtained where applicable. For animal studies, authors must confirm compliance with applicable animal welfare regulations and provide animal ethics committee approval details.
Authors must disclose all sources of financial or material support received for the study, if any.
If the manuscript involves any direct or indirect commercial relationship, product, drug, device, pharmaceutical company, or institutional support, authors must disclose the nature of the relationship in the cover letter and in the manuscript.
Authors must provide a conflict of interest statement and authorship contribution statement for all submissions. If there are no conflicts of interest, this should also be clearly stated.
All manuscripts submitted to the journal are screened for plagiarism using the ‘iThenticate’ software. Results indicating plagiarism may result in manuscripts being returned or rejected.
The editorial office may make minor language, formatting, and style corrections during the production process, provided that these changes do not alter the scientific content of the manuscript.
The Review Process
The journal applies a double-blind peer-review process. The manuscript is assigned to the Editor-in-Chief, who reviews the manuscript and makes an initial decision based on manuscript quality and editorial priorities. Manuscripts that pass the initial editorial evaluation are assigned to an Associate Editor and sent to at least two independent external reviewers with expertise in the relevant field. The Associate Editor evaluates the reviewers’ comments and recommendations and submits a recommendation to the Editor-in-Chief. The Editor-in-Chief makes a final decision based on editorial priorities, manuscript quality, and reviewer recommendations. If there are any conflicting recommendations from reviewers, the Editor-in-Chief can assign a new reviewer.
In case of any suspicion or claim regarding scientific shortcomings or ethical infringement, the Journal reserves the right to submit the manuscript to the supporting institutions or other authorities for investigation. The Journal accepts the responsibility of initiating action but does not undertake any responsibility for an actual investigation or any power of decision.
The Editorial Policies and General Guidelines for manuscript preparation are based on the current Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals by the International Committee of Medical Journal Editors.(http://www.icmje.org/).
Preparation of research articles, systematic reviews and meta-analyses must comply with study design guidelines:
CONSORT statement for randomized controlled trials (Moher D, Schultz KF, Altman D, for the CONSORT Group. The CONSORT statement revised recommendations for improving the quality of reports of parallel group randomized trials. JAMA 2001; 285: 1987-91) (http://www.consort-statement.org/);
PRISMA statement of preferred reporting items for systematic reviews and meta-analyses (Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 2009; 6(7): e1000097.) (http://www.prisma-statement.org/);
STARD checklist for the reporting of studies of diagnostic accuracy (Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al., for the STARD Group. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Ann Intern Med 2003;138:40-4.) (http://www.stard-statement.org/);
STROBE statement, a checklist of items that should be included in reports of observational studies (http://www.strobe-statement.org/);
MOOSE guidelines for meta-analysis and systematic reviews of observational studies (Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting Meta-analysis of observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-12).
Phytochemical profile/fingerprint analysis by advanced techniques (HPTLC, HPLC, LC-MS, etc) must be also presented in the studies performed with crude herbal extracts. The paper with preliminary qualitative experiments (tube experiments, TLC) for identification of the extracts are not accepted.
GENERAL GUIDELINES
Manuscripts can only be submitted electronically through the Journal Agent website (http://journalagent.com/tjps/) after creating an account. This system allows online submission and review.
Format: Manuscripts should be prepared using Microsoft Word, size A4 with 2.5 cm margins on all sides, 12 pt Arial font and 1.5 line spacing.
Abbreviations: Abbreviations should be defined at first mention and used consistently thereafter. Internationally accepted abbreviations should be used; refer to scientific writing guides as necessary.
Cover letter: The cover letter should include the manuscript type, confirmation that the manuscript is not under consideration elsewhere, conflict of interest statement, sources of funding or material support, and any relevant equipment or product information, where applicable.
ETHICS COMMITTEE APPROVAL
The Editorial Board and reviewers require ethics committee approval for studies involving humans, animals, human data, biological materials, or any research requiring ethical approval under applicable regulations and international guidelines.
For studies involving human participants, authors must provide the name of the ethics committee, approval date, and approval number, and must state that the study was conducted in accordance with the Declaration of Helsinki. Informed consent must be obtained where applicable and clearly stated in the Materials and Methods section.
For animal studies, authors must provide the name of the animal ethics committee, approval date, and approval number. Authors should also state that the study was conducted in accordance with applicable animal welfare regulations and the principles of replacement, reduction, and refinement (3Rs).
If authors state that ethics committee approval is not required, they must provide a clear justification. The Editorial Board may request additional documentation and will evaluate whether the justification is acceptable for editorial consideration.
For clinical trials and interventional studies, registration in a publicly accessible registry, such as ClinicalTrials.gov or a WHO-approved registry, is required where applicable. The registry name and registration number should be provided in the manuscript.
SIMILARITY
All submitted manuscripts are screened using iThenticate before editorial and peer-review evaluation. Manuscripts with a similarity rate above 15% are not accepted. Similarity reports are also reviewed by the editorial office to assess the nature, extent, and source of textual overlap.
REFERENCES
Authors are solely responsible for the accuracy of all references.
In-text citations: References should be indicated as a superscript immediately after the period/full stop of the relevant sentence. If the author(s) of a reference is/are indicated at the beginning of the sentence, this reference should be written as a superscript immediately after the author’s name. Authors should ensure that the literature review is comprehensive and balanced. Relevant studies conducted in Türkiye or by Turkish investigators may be cited when they are directly related to the manuscript’s subject, methodology, or findings.
Presentations presented in congresses, unpublished manuscripts, theses, Internet addresses, and personal interviews or experiences should not be indicated as references. If such references are used, they should be indicated in parentheses at the end of the relevant sentence in the text, without reference number and written in full, in order to clarify their nature.
References section: References should be numbered consecutively in the order in which they are first mentioned in the text. All authors should be listed regardless of number. The titles of Journals should be abbreviated according to the style used in the Index Medicus.
Reference Format
Journal: Last name(s) of the author(s) and initials, article title, publication title and its original abbreviation, publication date, volume, the inclusive page numbers. Example: Collin JR, Rathbun JE. Involutional entropion: a review with evaluation of a procedure. Arch Ophthalmol. 1978;96:1058-1064.
Book: Last name(s) of the author(s) and initials, book title, edition, place of publication, date of publication and inclusive page numbers of the extract cited.
Example: Herbert L. The Infectious Diseases (1st ed). Philadelphia; Mosby Harcourt; 1999:11;1-8.
Book Chapter: Last name(s) of the author(s) and initials, chapter title, book editors, book title, edition, place of publication, date of publication and inclusive page numbers of the cited piece.
Example: O’Brien TP, Green WR. Periocular Infections. In: Feigin RD, Cherry JD, eds. Textbook of Pediatric Infectious Diseases (4th ed). Philadelphia; W.B. Saunders Company;1998:1273-1278.
Books in which the editor and author are the same person: Last name(s) of the author(s) and initials, chapter title, book editors, book title, edition, place of publication, date of publication and inclusive page numbers of the cited piece. Example: Solcia E, Capella C, Kloppel G. Tumors of the exocrine pancreas. In: Solcia E, Capella C, Kloppel G, eds. Tumors of the Pancreas. 2nd ed. Washington: Armed Forces Institute of Pathology; 1997:145-210.
TABLES, GRAPHICS, FIGURES, AND IMAGES
All visual materials together with their legends should be located on separate pages that follow the main text.
Images: Images (pictures) should be numbered and include a brief title. Permission to reproduce pictures that were published elsewhere must be included. All pictures should be of the highest quality possible, in JPEG format, and at a minimum resolution of 300 dpi.
Tables, Graphics, Figures: All tables, graphics or figures should be enumerated according to their sequence within the text and a brief descriptive caption should be written. Any abbreviations used should be defined in the accompanying legend. Tables in particular should be explanatory and facilitate readers’ understanding of the manuscript, and should not repeat data presented in the main text.
MANUSCRIPT TYPES
Authors submitting their manuscripts should follow this guide for the authors. Editorial office may send the manuscript back in order to complete the standard requirements before proceeding for review.
Below are the word limits applied by the TJPS, specific to manuscript types;
Original Articles
Original articles may include clinical observations, new techniques, laboratory studies, or other original research in pharmaceutical sciences. Original research articles should include a title, structured abstract, keywords relevant to the content of the article, introduction, materials and methods, results, discussion, study limitations, conclusion, references, tables/figures/images, and acknowledgements sections. Title, abstract and key words should be written in English. The manuscript should be formatted in accordance with the above-mentioned guidelines and should not exceed 16 A4 pages.
Title Page: This page should include the title of the manuscript, short title, name(s) of the authors and author information. The following descriptions should be stated in the given order:
Title of the manuscript in English, as concise and explanatory as possible, without abbreviations, up to 135 characters.
Short title in English, up to 60 characters.
Full name(s), surname(s), and affiliation(s) of the author(s), without abbreviations or academic titles.
Name, address, e-mail address, phone number, and fax number of the corresponding author.
The place and date of the scientific meeting at which the manuscript was presented and the abstract book in which it was published, if applicable.
Abstract: A summary of the manuscript should be written in English. References should not be cited in the abstract. Use of abbreviations should be avoided as much as possible; if any abbreviations are used, they must be taken into consideration independently of the abbreviations used in the text. For original articles, the structured abstract should include the following sub-headings:
Objectives: The aim of the study should be clearly stated.
Materials and Methods: The study and standard criteria used should be defined; it should also be indicated whether the study is randomized or not, whether it is retrospective or prospective, and the statistical methods applied should be indicated, if applicable.
Results: The detailed results of the study should be given and the statistical significance level should be indicated.
Conclusion: Should summarize the results of the study, the clinical applicability of the results should be defined, and the favorable and unfavorable aspects should be declared.
Keywords: A list of minimum 3, but no more than 5 key words must follow the abstract. Keywords in English should be consistent with Medical Subject Headings (MESH).
Original research articles should have the following sections:
Introduction: Should consist of a brief explanation of the topic and indicate the objective of the study, supported by information from the literature.
Materials and Methods: The study plan should be clearly described, indicating whether the study is randomized or not, whether it is retrospective or prospective, the number of trials, the characteristics, and the statistical methods used, and these methods and their analyses should be specified under the statistical analysis subsection.
Results: The results of the study should be stated, with tables/figures given in numerical order; the results should be evaluated according to the statistical analysis methods applied. See General Guidelines for details about the preparation of visual material.
Discussion: The study results should be discussed in terms of their favorable and unfavorable aspects and they should be compared with the literature. The conclusion of the study should be highlighted.
Study Limitations: Limitations of the study should be discussed. In addition, an evaluation of the implications of the obtained findings/results for future research should be outlined.
Conclusion: The conclusion of the study should be highlighted.
Acknowledgements: Any technical or financial support or editorial contributions (statistical analysis and evaluation) towards the study should appear at the end of the article.
References: Authors are responsible for the accuracy of the references. See General Guidelines for details about the usage and formatting required.
Review Articles
Review articles are considered only upon invitation by the Editorial Board. Unsolicited review submissions are not considered unless prior approval has been obtained from the Editorial Board.
Review articles may address any aspect of clinical, laboratory, or pharmaceutical sciences. They should provide an in-depth, independent, and objective analysis of current evidence and identify directions for future research.
Review articles should include a title in English, an unstructured abstract, keywords, main text, references, and, where applicable, tables and figures. All cited sources should be clearly referenced. The manuscript should not exceed 25 A4 pages when formatted according to the journal’s requirements.
Letter to the Editor
Letters to the Editor may be submitted in response to work that has been published in the Journal. Letters should be short commentaries related to specific points of agreement or disagreement with the published work. Letters should not exceed 1,000 words, five complete references, and three authors.
